AzTrials
AzTrials

Upper Gastrointestinal BleedingTRIAGENCT03090945

Pediatric Acute Gastrointestinal Bleeding Registry

An observational study of Upper Gastrointestinal Bleeding and Gastro Intestinal Bleeding, run by Boston Children's Hospital at 3 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. Read more about this study

Who is it for?
Ages Up to 21 years
What is being tested?
This is an obsevational cohort study
How many people
300 participants
Where
3 sitesUnited States
Study dates
1 May 2017to 1 Dec 2023
How long will I take part?
6 Months
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 21 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: All pediatric patients who present to the hospital or are currently hospitalized and presented with clinical signs of upper gastric intestinal bleeding that are severe enough that warrant the physician to perform an upper endoscopy.

Who may be able to join

  • All pediatric patients will selected based on signs and symptoms of upper gastrointestinal bleeding and their need to have an upper endoscopy performed.

Who cannot join

  • None

Trial locations and contacts

3 sites in 1 country.

United States3 sites, 3 recruiting
  • Boston Childrens Hospital

    Boston, Massachusetts, 02115

    Michael A Manfredi, MD

    Recruiting
  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611

    Lee Bass, MD

    Recruiting
  • Texas Children's Hospital

    Houston, Texas, 77030

    Douglas Fishman, MD

    Recruiting

Other trials in United States

About this study

Official title: Pediatric Acute Bleeding Registry: Identification of Clinical, Laboratory and Endoscopic Risk Factors Associated With Pediatric Upper Gastrointestinal Bleeding

The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. If a predictive/risk stratification relationship exists, these data could permit a more effective triaging and intervention scheme in pediatric patients presenting with complaints of gastrointestinal bleeding. In addition we want to get a better understanding of the re-bleeding rate after endoscopic therapy for upper GI bleeding and if there are any identifiable risk factors for re-bleeding. Lastly we want to understand best practice management for upper GI bleeding.

Read the detailed description
  1. Specific Aims/Objectives:

The goal of this study is to identify significant clinical and laboratory risk factors in pediatric patients with significant upper gastrointestinal bleeding. This is defined as bleeding that necessitates an upper endoscopic evaluation to either diagnose or treat upper GI bleeding during their hospital admission. If a predictive/risk stratification relationship exists, these data could permit a more effective triaging and intervention scheme in pediatric patients presenting with complaints of gastrointestinal bleeding. In addition we want to get a better understanding of the re-bleeding rate after endoscopic therapy for upper GI bleeding and if there are any identifiable risk factors for re-bleeding. Lastly we want to understand best practice management for upper GI bleeding.

  1. Background and Significance:

Gastrointestinal (GI) hemorrhage is a potentially life-threatening presentation that the pediatric gastroenterologist must recognize, and manage appropriately. Classification is generally divided between upper or lower GI bleeding, based on the origin of bleeding relative to hemorrhages the Ligament of Treitz. The incidence of GI bleeding in children is not well established in the pediatric population. For upper GI bleeds most large, prospective studies have assessed incidence in pediatric critical care settings. In one prospective study of 984 patients, upper GI bleeds occurred in 6.4% of admissions receiving on prophylactic therapy. Other studies have shown upper GI bleeding in as many as 25% of pediatric intensive care admissions without prophylaxis. There is no data on the incidence of pediatric GI bleeds that requires endoscopic therapy.

Pediatric studies are lacking with respect to risk stratification and decisional algorithms in managing pediatric acute upper gastrointestinal bleeding. Adult literature supports accurate stratification of risk based on clinical history, physical examination, and laboratory measures. Additionally, endoscopic interventions not only allow for therapeutic interventions but also prognosticate based on visual findings. Similar pediatric literature is not available thus giving rise to large amounts of variability both center to center as well as within centers regarding management decision making.

  1. Design and Methods:
  • Prospective, observational analysis of inpatient and ambulatory records of pediatric patients at Boston Children's Hospital beginning upon IRB approval.
  • We will identify pediatric patients </= 21 years old presenting acutely to the emergency room, ambulatory clinic or as current inpatients who require endoscopic evaluation for acute upper gastrointestinal bleed and potential treatment.
  • Data collected will include clinical signs and symptoms and physical exam features, laboratory studies and endoscopic findings
  • Identified patients will then be followed prospectively for outcomes data collection.
  • Data collection will include:
  • Clinical history of bleeding onset, acuity, amount, frequency and prior history of gastrointestinal bleed.
  • Medication history
  • Physical examination data including vital signs (heart rate, blood pressure, and oxygen saturation)
  • Laboratory data including
  • Complete blood count
  • Inflammatory markers (ESR and CRP)
  • Liver panel
  • Complete Metabolic Panel
  • Urinanalysis
  • Endoscopic findings as well as data from interventions (cautery, clips, injections)
  • Medical management decisions (acid suppression therapy, oral intake, frequency of laboratory measurement)
  • Outcome data including re-bleeding rates (with respect to endoscopic intervention), laboratory measures, and length of stay.
Being tested
This is an obsevational cohort study
Keywords
Endoscopy, GI Bleeding, Pediatrics, Upper Gastrointestinal Bleeding, Gastro Intestinal Bleeding
Medical subject headings
Gastrointestinal Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • This is an obsevational cohort studyOther

    no intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Develop a predictive/risk stratification algorithm for pediatric upper gastric intestinal bleeding

    Identification of prognostic clinical history, physical examination, and laboratory measure risk factors that can predict/risk stratifies significant upper gastrointestinal bleeding in children.

    Measured: 3 years

Secondary outcomes (5)
  1. Medical Management Strategies

    Identify successful medical management strategies in pediatric patients diagnosed with acute upper gastrointestinal bleed

    Measured: 3 years

  2. Endoscopic Management Strategies

    Identify successful endoscopic and medical interventions measured by incidence rate of re-bleeding

    Measured: 3 years

  3. Re-Bleeding Risk Factors

    Identify pre-existing risk factors or clinical factors associated with re-bleeding rates following initial endoscopic or surgical intervention.

    Measured: 3 years

  4. Identify Average length of Stay for Upper Gastrointestinal Bleeding

    Identify length of medical stabilization and/or observation prior to either endoscopic or surgical intervention measured in hours or days in medical supervision and subsequent outcome, incidence of re-bleeding,

    Measured: 3 years

  5. Identify the incidence of significant upper gastrointestinal bleed in all pediatric hospital admission.

    Identify the incidence of significant upper gastrointestinal bleed in all pediatric hospital admission.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2017
  2. Study start1 May 2017
  3. Primary completion1 Mar 2023 (estimated)
  4. Study completion1 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
6 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT03090945
Sponsor's protocol ID
P00021336
Acronym
TRIAGE
Status last verified
Sep 2020
First submitted
20 Mar 2017
Last updated
16 Sep 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Upper Gastrointestinal Bleeding and Gastro Intestinal Bleeding, run by Boston Children's Hospital at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 16 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Michael A Manfredi, MD (617-355-6058, michael.manfredi@childrens.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Develop a predictive/risk stratification algorithm for pediatric upper gastric intestinal bleeding (time frame: 3 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in